MDS patients that resist the treatment of DNA demethylating agent 5-aza-2-deoxycytidine had a higher expression of TWIST1 as compared to responsive patients, further highlighting its role in therapeutic resistance [46]. Here, TWIST1 is linked to myelodysplastic syndrome.